Analysis of molecular pathological factors of unfavorable prognosis for young cervical cancer patients.
The aim of this study was to explore the molecular pathological characteristics of cervical cancer in women aged below 35, disclose the factors that indicate the unfavorable prognosis, and provide some useful targets for improving therapeutic outcome.


METHODS
64 cases of pathological data originating from cervical cancer patients aged below 35 served as the study group to perform a retrospective research, and pathological data from 90 cases of cervical cancer patients beyond age 35, who underwent treatment during the same time, were selected at random as the reference group. Immunohistochemistry and quantified image analysis were utilized to detect synchronously the protein expression difference of survivin and p27 between the 2 groups.


RESULTS
The total 5-year survival rate of the study group was 65.6% compared to 84.4% in the reference group, while the lymph node metastasis rate was 25% compared to 12.2% in the reference group. Both differences were statistically significant (p < 0.05). Survivin expression is much greater in the study group than in the reference group (p < 0.05); there is no statistical difference of the p27 expression between the 2 groups (p > 0.05), but p27 expression is related to lymph node metastasis.


CONCLUSIONS
Younger female patients have a worse prognosis than older ones, and survivin expression is associated with poor prognosis. Targeting these molecular factors may lead to a hopeful biomedical therapy to improve the prognosis of young female cervical cancer patients.
Yi
Luo
L
Department of Gynecology and Obstetrics, the Affiliated Taihe Hospital of Yunyang Medical College, Shiyan, China. yunyiluoyi@sina.com
Jian
Wang
W
Chang-yin
Zhao
Z
Jing
Feng
F
Shuang-yun
Chen
C
Xuanbing
Tang
T
D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis*; D002648:Child; D002681:China / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000032:analysis*; D009363:Neoplasm Proteins / Q000032:analysis*; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis*; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D015996:Survival Rate; D000077022:Survivin; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000453:epidemiology* / Q000378:metabolism
C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D018809:Proliferating Cell Nuclear Antigen; D000077022:Survivin; C413374:p27 antigen